Merck invests in Moderna
Merck is investing $125 million in Moderna under a new deal that expands the firms’ 2016 partnership to develop messenger RNA cancer vaccines.
Read More
Tag: mRNA-5671
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
